Etirinotecan pegol: an option for late-stage breast cancer?
Mené sur 70 patientes atteintes d'un cancer métastatique du sein, cet essai de phase II évalue l'efficacité, du point de vue du pourcentage de patientes avec réponse objective, et la toxicité de l'etirinotecan pegol, un inhibiteur de la topoisomérase I en traitement de deuxième ou troisième ligne
Breast cancer is the most common malignancy in women in developed countries. Although breast cancer mortality has decreased in recent years, the disease is still the leading cause of cancer-related deaths in women. Most women who have recurrence of a primary breast cancer will have previously received taxane and anthracycline treatment in the adjuvant setting. Accordingly, very few treatment options are available for metastatic disease. Etirinotecan pegol (NKTR-102) is a long-acting inhibitor of ...
The Lancet Oncology , commentaire, 2012